-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
One Yestar Healthcare Holdings Company Limited (HKG:2393) Analyst Has Been Cutting Their Forecasts
One Yestar Healthcare Holdings Company Limited (HKG:2393) Analyst Has Been Cutting Their Forecasts
The latest analyst coverage could presage a bad day for Yestar Healthcare Holdings Company Limited (HKG:2393), with the covering analyst making across-the-board cuts to their statutory estimates that might leave shareholders a little shell-shocked. There was a fairly draconian cut to their revenue estimates, perhaps an implicit admission that previous forecasts were much too optimistic. Shares are up 4.4% to HK$0.71 in the past week. We'd be curious to see if the downgrade is enough to reverse investor sentiment on the business.
Following the downgrade, the consensus from single analyst covering Yestar Healthcare Holdings is for revenues of CN¥4.3b in 2022, implying a measurable 6.1% decline in sales compared to the last 12 months. Before the latest update, the analyst was foreseeing CN¥5.2b of revenue in 2022. The consensus view seems to have become more pessimistic on Yestar Healthcare Holdings, noting the substantial drop in revenue estimates in this update.
Check out our latest analysis for Yestar Healthcare Holdings
SEHK:2393 Earnings and Revenue Growth August 29th 2022Looking at the bigger picture now, one of the ways we can make sense of these forecasts is to see how they measure up against both past performance and industry growth estimates. We would highlight that sales are expected to reverse, with a forecast 6.1% annualised revenue decline to the end of 2022. That is a notable change from historical growth of 4.3% over the last five years. By contrast, our data suggests that other companies (with analyst coverage) in the same industry are forecast to see their revenue grow 39% annually for the foreseeable future. It's pretty clear that Yestar Healthcare Holdings' revenues are expected to perform substantially worse than the wider industry.
The Bottom Line
The most important thing to take away is that the analyst cut their revenue estimates for this year. They also expect company revenue to perform worse than the wider market. Often, one downgrade can set off a daisy-chain of cuts, especially if an industry is in decline. So we wouldn't be surprised if the market became a lot more cautious on Yestar Healthcare Holdings after today.
Thirsting for more data? We have forecasts for Yestar Healthcare Holdings from one covering analyst, and you can see them free on our platform here.
Of course, seeing company management invest large sums of money in a stock can be just as useful as knowing whether analysts are downgrading their estimates. So you may also wish to search this free list of stocks that insiders are buying.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
最新的分析师报道可能预示着糟糕的一天 星星医疗控股有限公司 (HKG: 2393),封面分析师全面削减了法定估算,这可能会让股东感到有些震惊。他们对收入估计的下调相当严厉,这可能是隐含地承认先前的预测过于乐观。过去一周,股价上涨了4.4%,至0.71港元。我们很想知道降级是否足以扭转投资者对该业务的情绪。
降级后,负责Yestar Healthcare Holdings的单一分析师一致认为,2022年的收入为43亿元人民币,这意味着与过去12个月相比,销售额明显下降了6.1%。在最新更新之前,分析师预计 2022 年的收入将达到 52 亿人民币。对Yestar Healthcare Holdings的共识似乎变得更加悲观,他们指出,本次更新中的收入预期大幅下降。
查看我们对Yestar医疗控股的最新分析
SEHK: 2393 收益与收入增长 2022 年 8 月 29 日从现在的大局来看,我们理解这些预测的方法之一是看看它们如何与过去的表现和行业增长预期相比较。我们要强调的是,预计销售将逆转,预计到2022年底,年化收入将下降6.1%。与过去五年4.3%的历史增长相比,这是一个显著的变化。相比之下,我们的数据表明,预计在可预见的将来,同一行业的其他公司(有分析师覆盖范围)的收入将每年增长39%。很明显,预计Yestar Healthcare Holdings的收入表现将比整个行业差得多。
底线
最重要的一点是,分析师下调了今年的收入预期。他们还预计,公司收入的表现将比整个市场差。通常,一次降级可以引发一连串的削减,尤其是在行业衰退的情况下。因此,如果今天之后市场对Yestar Healthcare Holdings变得更加谨慎,我们也不会感到惊讶。
渴望更多数据?我们有一位封面分析师对Yestar Healthcare Holdings的预测,你可以在这里在我们的平台上免费查看。
当然,看看公司管理层 投入大量资金 在股票中可能和知道分析师是否下调了他们的估计值一样有用。所以你可能还想搜索这个 免费的 内部人士正在购买的股票清单。
对这篇文章有反馈吗?对内容感到担忧? 取得联系 直接和我们联系。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St 的这篇文章本质上是一般性的。 我们仅使用不偏不倚的方法根据历史数据和分析师预测提供评论,我们的文章并非旨在提供财务建议。 它不构成买入或卖出任何股票的建议,也没有考虑您的目标或财务状况。我们的目标是为您提供由基本面数据驱动的长期重点分析。请注意,我们的分析可能未将最新的价格敏感型公司公告或定性材料考虑在内。简而言之,华尔街对上述任何股票都没有头寸。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧